Satsuma Pharmaceuticals, Inc.
STSADelisted Jun 8, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001692830
Satsuma Pharmaceuticals, Inc. was delisted on Jun 8, 2023; its insiders filed their last Form 4 on Jun 12, 2023; 31 institutions reported holding it in 13F filings for Q1 2023, worth $12.7M in total; no superinvestor held it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:58 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|
| Period end | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
| Filing | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 28, 2023 | Mar 15, 2022 | Mar 25, 2021 | Mar 10, 2020 |
| Operating expenses | $70.9M | $51.2M | $48.3M | $28.9M |
| Research and development | $44.1M | $37.6M | $36.3M | $24.2M |
| Selling, general and administrative | $15.1M | $13.5M | $12.1M | $4.68M |
| Operating income | -$70.9M | -$51.2M | -$48.3M | -$28.9M |
| Interest expense | $13.0K | $163.0K | $350.0K | $482.0K |
| Income tax | $0 | $0 | $1.00K | $1.00K |
| Net income | -$70.1M | -$51.2M | -$47.6M | -$28.2M |
| EPS, basic | $-2.19 | – | – | – |
| EPS, diluted | $-2.19 | – | – | – |
| Weighted shares, basic | 32.0M | – | – | – |
| Weighted shares, diluted | 32.0M | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|
| Period end | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
| Filing | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 28, 2023 | Mar 15, 2022 | Mar 25, 2021 | Mar 10, 2020 |
| Cash and equivalents | $16.4M | $15.8M | $36.3M | $22.8M |
| Total current assets | $54.8M | $99.8M | $73.8M | $114.7M |
| Property, plant and equipment | $0 | $6.79M | $6.47M | $832.0K |
| Total assets | $54.9M | $109.8M | $81.0M | $126.3M |
| Accounts payable | $1.91M | $1.47M | $3.38M | $4.28M |
| Short-term debt | – | $1.08M | $1.99M | $1.98M |
| Total current liabilities | $8.12M | $8.49M | $8.05M | $7.97M |
| Long-term debt | – | $833.0K | $2.83M | $4.83M |
| Total liabilities | $8.12M | $8.49M | $9.10M | $10.9M |
| Shareholders' equity | $46.8M | $101.3M | $71.9M | $115.3M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|
| Period end | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
| Filing | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 28, 2023 | Mar 15, 2022 | Mar 25, 2021 | Mar 10, 2020 |
| Operating cash flow | -$51.5M | -$43.0M | -$42.3M | -$29.6M |
| Capital expenditures | $472.0K | $2.03M | $5.17M | $551.0K |
| Free cash flow | -$52.0M | -$45.0M | -$47.5M | -$30.2M |
| Stock-based compensation | $5.71M | $5.36M | $4.02M | $747.0K |
| Investing cash flow | $43.4M | -$50.8M | $58.0M | -$95.9M |
| Financing cash flow | $8.74M | $73.3M | -$2.10M | $143.1M |
| Net change in cash | $594.0K | -$20.5M | $13.6M | $17.6M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| May 8, 2023 | 33.2M | +5.1% | SEC |
| Mar 22, 2023 | 33.2M | +5.1% | SEC |
| Oct 31, 2022 | 33.1M | +5.1% | SEC |
| Aug 4, 2022 | 31.6M | +0.2% | SEC |
| May 6, 2022 | 31.5M | +0.1% | SEC |
| Mar 11, 2022 | 31.5M | +0.1% | SEC |
| Nov 5, 2021 | 31.5M | +81.0% | SEC |
| Aug 6, 2021 | 31.5M | +81.1% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.